Stifel Nicolaus Reiterates Buy Rating for AnaptysBio, Inc. (ANAB)
AnaptysBio, Inc. (NASDAQ:ANAB)‘s stock had its “buy” rating reissued by investment analysts at Stifel Nicolaus in a report released on Tuesday. They presently have a $35.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 8.02% from the stock’s current price.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. Robert W. Baird began coverage on shares of AnaptysBio in a report on Monday, July 10th. They set an “outperform” rating and a $36.00 price target for the company. Finally, Credit Suisse Group boosted their price target on shares of AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, August 25th. Six investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $36.00.
AnaptysBio (NASDAQ:ANAB) traded up 0.880% during midday trading on Tuesday, reaching $32.685. 116,512 shares of the company were exchanged. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $33.58. The company’s market capitalization is $664.88 million. The firm has a 50-day moving average price of $24.56 and a 200-day moving average price of $25.08.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.29. The firm had revenue of $7.00 million for the quarter, compared to analyst estimates of $3.45 million. Equities research analysts anticipate that AnaptysBio will post ($1.96) earnings per share for the current fiscal year.
In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the sale, the insider now owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The disclosure for this sale can be found here. Insiders have sold a total of 1,133,940 shares of company stock valued at $24,223,316 in the last 90 days.
Several large investors have recently modified their holdings of the company. DAFNA Capital Management LLC lifted its position in shares of AnaptysBio by 22.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after buying an additional 1,000 shares during the last quarter. Teachers Advisors LLC raised its position in AnaptysBio by 23.4% in the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,807 shares during the last quarter. Bank of America Corp DE purchased a new stake in AnaptysBio in the 1st quarter valued at $123,000. TIAA CREF Investment Management LLC raised its position in AnaptysBio by 69.2% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 13,844 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 5,663 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in AnaptysBio by 46.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,744 shares of the biotechnology company’s stock valued at $473,000 after purchasing an additional 6,297 shares during the last quarter. Institutional investors and hedge funds own 71.35% of the company’s stock.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.